Over time, cancer cells can evolve to become resistant to treatment, more aggressive, and metastatic—capable of spreading to additional sites in the body and forming new tumors. The more of these traits that a cancer evolves, ...
May 5, 2022
0
89
About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make ...
Apr 28, 2022
0
34
Cancer researchers at Case Western Reserve University School of Medicine say they have successfully suppressed the growth of some solid tumors in research models by manipulating immune cells known as macrophages.
Apr 20, 2022
0
101
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Apr 11, 2022
0
2
Non-small cell lung cancer (NSCLC) is a devastating disease and the leading cause of American cancer deaths. Even patients suitable for tumor removal have a 50% mortality rate. But University of Missouri School of Medicine ...
Apr 6, 2022
0
35
Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them. The findings, ...
Mar 24, 2022
0
76
Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and Albert ...
Mar 16, 2022
0
57
Macrophages are immune cells crucial for immune response, tissue repair, and the removal of cancer cells. Scientists see macrophages as promising living therapeutics. However, to be effectively used for therapies, macrophages ...
Feb 25, 2022
0
188
Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.
Feb 10, 2022
0
11
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. ...
Feb 9, 2022
0
40
